South Korea has recently unveiled a US$2bn plan to emerge as a global COVID-19vaccine production hub and become one of the top five manufacturing bases by 2025.
The sales of final dosage forms in the first half of 2021 totaled 109,5 million euros and compared to the first half of 2020 increased by 21.9 million euros.